Galantamine Tablet, Film Coated
Product Images NDC 72162-2566

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Galantamine (NDC 72162-2566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 21 Weeks (5 Months) Of Treatment (Galantamine Fig1)

Figure 1: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 21 Weeks (5 Months) Of Treatment (Galantamine Fig1)
A line graph showing the mean change from baseline in ADAS-cog Score over 21 weeks of treatment for placebo and three Galantamine dosage groups: 8 mg/day, 16 mg/day, and 24 mg/day. The vertical axis represents improvement or decline in score, and the horizontal axis shows weeks of treatment, with plotted data points and error bars for each group.*
FDA Label Image

Figure 10: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 13 Weeks Of Treatment (Galantamine Fig10)

Figure 10: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 13 Weeks Of Treatment (Galantamine Fig10)
A line graph showing mean change from baseline in ADAS-cog score over 13 weeks of treatment. It compares placebo with 24 or 32 mg/day doses, indicating improvement trends over time, with error bars representing standard error. The x-axis shows weeks of treatment (0, 4, 13), and the y-axis shows change scores from -2 to 2.*
FDA Label Image

Figure 11: Cumulative Percentage Of Patients Completing 13 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 90%, 24 To 32 mg/day 67%. (Galantamine Fig11)

Figure 11: Cumulative Percentage Of Patients Completing 13 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 90%, 24 To 32 mg/day 67%. (Galantamine Fig11)
A cumulative percentage of patients graph showing ADAS-cog score changes from baseline on the x-axis and cumulative percentage on the y-axis. The plot compares placebo versus a 24 or 32 mg/day treatment group, with data points represented by circles and diamonds respectively, indicating cognitive changes ranging from -15 to +15 points.*
FDA Label Image

Figure 12 (Galantamine Fig12)

Figure 12 (Galantamine Fig12)
A bar chart comparing the percentage of patients by CIBIC-plus Rating categories between placebo and 24 or 32 mg/day Galantamine treatment groups. Categories on the x-axis include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse, with corresponding patient percentages on the y-axis.*
FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 21 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 84%, 8 mg/day 77%, 16 mg/day 78% And 24 mg/day 78%. (Galantamine Fig2)

Figure 2: Cumulative Percentage Of Patients Completing 21 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 84%, 8 mg/day 77%, 16 mg/day 78% And 24 mg/day 78%. (Galantamine Fig2)
A cumulative percentage line graph showing ADAS-cog change from baseline for patients given Placebo, 8 mg/day, 16 mg/day, and 24 mg/day doses. The x-axis represents the change in ADAS-cog score from -15 to +15, with vertical lines indicating -10, -7, -4 points, and no change. The y-axis shows cumulative percentage of patients from 0% to 100%.*
FDA Label Image

Figure 3: Distribution Of Cibic-plus Ratings At Week 21 (Galantamine Fig3)

Figure 3: Distribution Of Cibic-plus Ratings At Week 21 (Galantamine Fig3)
A bar chart showing the distribution of patients across CIBIC-plus Rating categories comparing placebo and three galantamine dosage groups (8 mg/day, 16 mg/day, 24 mg/day). The x-axis lists rating categories from Markedly Improved to Markedly Worse, while the y-axis shows the percentage of patients. Different shading distinguishes each treatment group within the rating categories.*
FDA Label Image

Figure 4: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig4)

Figure 4: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig4)
A line chart showing mean change from baseline in ADAS-cog score over 26 weeks of treatment. The chart compares three groups: placebo, 24 mg/day, and 32 mg/day doses. The vertical axis shows score changes indicating improvement or decline, and the horizontal axis indicates weeks of treatment (0, 3, 13, 26).*
FDA Label Image

Figure 5 (Galantamine Fig5)

Figure 5 (Galantamine Fig5)
A line graph showing the cumulative percentage of patients versus ADAS-cog change from baseline. It compares three groups: placebo (circles), 24 mg/day (squares), and 32 mg/day (triangles). The graph includes vertical reference lines at -10, -7, and -4 points, and a 'No Change' line at zero on the ADAS-cog axis.*
FDA Label Image

Figure 6: Distribution Of Cibic-plus Ratings At Week 26 (Galantamine Fig6)

Figure 6: Distribution Of Cibic-plus Ratings At Week 26 (Galantamine Fig6)
A bar graph showing CIBIC-plus ratings of patients divided into groups by treatment: Placebo, 24 mg/day, and 32 mg/day. The vertical axis represents the percentage of patients, while the horizontal axis categorizes ratings from Markedly Improved to Markedly Worse. The highest percentages appear under 'No Change' for all groups, with varying distributions across other categories.*
FDA Label Image

Figure 7: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig7)

Figure 7: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig7)
Line graph showing mean change from baseline in ADAS-cog score over 26 weeks of treatment for Galantamine at doses of 24 mg/day, 32 mg/day, and placebo. The y-axis represents mean change with improvement above baseline and decline below, while the x-axis denotes weeks of treatment at intervals 0, 3, 13, and 26. Data points for active doses show improvement, while placebo shows decline over time.*
FDA Label Image

Figure 8: Cumulative Percentage Of Patients Completing 26 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 87%, 24 mg/day 80%, And 32 mg/day 75%. (Galantamine Fig8)

Figure 8: Cumulative Percentage Of Patients Completing 26 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 87%, 24 mg/day 80%, And 32 mg/day 75%. (Galantamine Fig8)
A cumulative percentage plot showing ADAS-cog change from baseline on the x-axis and cumulative percentage of patients on the y-axis, comparing placebo, 24 mg/day, and 32 mg/day dosing groups of Galantamine. The chart includes markers for -10, -7, -4 points and no change on the x-axis to indicate cognitive changes over time.*
FDA Label Image

Figure 9: Distribution Of Cibic-plus Rating At Week 26 (Galantamine Fig9)

Figure 9: Distribution Of Cibic-plus Rating At Week 26 (Galantamine Fig9)
A bar graph displaying the percentage of patients by CGI-type Plus Rating categories for Placebo, 24 mg/day, and 32 mg/day treatment groups. Categories on the x-axis include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. The y-axis shows percentage ranging from 0 to 60.*
FDA Label Image

Chemical Structure (Galantamine Str)

Chemical Structure (Galantamine Str)
Chemical structure of Galantamine hydrobromide, showing its fused ring system with hydroxyl, methoxy, and methylamine functional groups.*
FDA Label Image

Label (Lbl721622566)

Label (Lbl721622566)
Label for Galantamine Tablets, USP 8 mg film-coated tablets. The package contains 60 tablets and is relabeled by Bryant Ranch Prepack. It is manufactured by Aurobindo Pharma Limited. The label includes the NDC number 72162-2566, storage instructions, and QR codes for product literature and package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.